PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of wtpaEurope PMCEurope PMC Funders GroupSubmit a Manuscript
 
J Immunol. Author manuscript; available in PMC 2010 November 30.
Published in final edited form as:
PMCID: PMC2993923
EMSID: UKMS32951

TOLERIZATION OF A TYPE I ALLERGIC IMMUNE RESPONSE THROUGH TRANSPLANTATION OF GENETICALLY MODIFIED HEMATOPOIETIC STEM CELLS1

Abstract

Allergy represents a hypersensitivity disease which affects more than 25% of the population in industrialized countries. The underlying type I allergic immune reaction occurs in predisposed atopic individuals in response to otherwise harmless antigens (i.e. allergens) and is characterized by the production of allergen-specific IgE, an allergen-specific T cell response and the release of biologically active mediators such as histamine from mast cells and basophils. Regimens permanently tolerizing an allergic immune response still need to be developed. We therefore retrovirally transduced murine hematopoietic stem cells (HSC) to express the major grass pollen allergen Phl p 5 on their cell membrane. Transplantation of these genetically modified HSC led to durable multi-lineage molecular chimerism and permanent immunological tolerance towards the introduced allergen at the B cell, T cell and effector cell levels. Notably, Phl p 5-specific serum IgE (and IgG) remained undetectable and T cell non-responsiveness persisted throughout follow-up (40 weeks). Besides, mediator release was specifically absent in in vitro and in vivo assays. B cell, T cell and effector cell responses to an unrelated control allergen (Bet v 1) were unperturbed demonstrating specificity of this tolerance protocol. We thus describe a novel cell-based strategy for the prevention of allergy.

Keywords: Allergy, Molecular Biology, Antigens/Peptides/Epitopes, Tolerance/Suppression/Anergy

INTRODUCTION

The pathophysiological hallmark of type I allergy is the Th2 cell-driven production of IgE against otherwise harmless antigens (i.e. allergens) in predisposed atopic individuals. 1,2 IgE-mediated allergy manifests itself clinically either locally (e.g. as hay fever, allergic asthma, or food allergy) or systemically, as is the case in anaphylaxis. Although infrequent, anaphylaxis is an acute life-threatening condition (e.g. induced by food allergens or insect venoms). 3 Allergy is mainly being treated symptomatically by various drugs which are associated with considerable side-effects and cost.

Allergen-specific immunotherapy, whereby increasing doses of the sensitizing allergen are repeatedly administered in the form of crude extracts, is employed in selected patients and is currently the only allergen-specific treatment of allergy. 4 However, allergen-specific immunotherapy is associated with limited effectiveness and substantial risks, as exemplified by anaphylactic reactions or therapy-induced sensitization to additional allergens. 5 Today the molecular structure of most common allergens has been revealed and advanced experimental allergen-specific strategies have been developed. 6 They include the use of allergen-derived T cell epitope-containing peptides 7, genetically engineered allergens 5 and DNA-based forms of treatment. 8 Several experimental approaches for tolerance induction in allergy have also been explored but are characterized by limited robustness and relatively short-lived effects. 9-11 So far no robust allergen-specific tolerance approach has been reported that permanently prevents allergy.

It is one of the main features of the immune system to be tolerant towards self. 12 A major mechanism of self-tolerance is mediated by subpopulations of hematopoietic cells expressing self antigens. 13;14 This principle has been emulated in organ transplantation by introducing donor HSC into the recipient in a way to create a chimeric state in which recipient and donor bone marrow (BM) co-exist, thereby inducing tolerance towards donor (allo)antigens. 15;16 Alternatively, disease-associated antigen(s) can be introduced into an individual by transplanting autologous (i.e. in the experimental rodent setting syngeneic) HSC after they have been genetically modified in vitro to express the relevant antigen(s), leading to so-called molecular chimerism. 17 Where successful, regimens relying on hematopoietic chimerism are characterized by a state of antigen-specific tolerance that is particularly robust and long-lasting.

Molecular chimerism models have been used experimentally to tolerize an allogeneic immune response (using single MHC antigens), 18,19 a xenogeneic response (introducing the enzyme alpha (1,3) galactosyltransferase) 20 and selected autoimmune responses. 21,22 However, other studies failed to achieve tolerance in particular autoimmune disease models 23 and even enhanced the susceptibility for disease development. No studies attempting tolerization of the distinct allergic immune response through molecular chimerism have been reported so far.

We wanted to investigate whether the immune response of IgE-mediated allergy can be tolerized by transplantation of syngeneic HSC expressing an allergen.

MATERIALS AND METHODS

Animals

Female BALB/c mice were purchased from Charles River Laboratories (Sulzfeld, Germany). All mice were housed under specific pathogen-free conditions and were used between 6 and 12 weeks of age. All experiments were approved by the local review board of the Medical University of Vienna, and were performed in accordance with national and international guidelines of laboratory animal care.

Retroviral constructs and production of retroviruses

To generate membrane-anchored Phl p 5, full length Phl p 5 (accession number ×74735) was fused to a signal sequence and a transmembrane domain (TMD) (both pDisplay, Invitrogen, Carlsbad, CA) by overlapping PCR technique. 24 The original signal sequence of Phl p 5 was replaced by the murine immunoglobulin signal sequence pDisplay. Primer sequences are used as follows: leader peptide: 5′-GGCGCCATGGAGACAGACACACTCCTG-3′, 5′-GTAACCGAGATCGGCGTCACCAGTGGA-3′, Phl p 5: 5′-ACTGGTGACGCCGATCTCGGTTAC-3′, 5′-GCC CAC AGC GAC TTT GTA GCC ACC-3′, TMD: 5′-TACAAAGTCGCTGTGGGC-3′, 5′-GGCGGATCCTAACGTGGCTTCTTCTG-3′. PCR product was cloned into the retroviral vector pMMP NcoI and BamHI sites resulting in pMMP-Phl p 5-TM. The start codon was inserted with the Nco I site, the stop codon was inserted with the BamHI site. For virus production plasmids pMMP-Phl p 5-TM, pMD.G, encoding for VSV-G protein and pMLV, encoding for viral proteins gag and pol, were cotransfected using the calcium phosphate method 25 into 293 T cells resulting in VSV-Phl p 5-TM viruses. Viral supernatants were concentrated by ultracentrifugation (33620 g for 2h). Mock viruses were produced in the same manner using empty pMMP vector.

Retroviral transduction of bone marrow cells

BALB/c donors were injected intraperitoneally with 5-fluorouracil (150mg/KG) 7 days before BM isolation. 26 Mice were sacrificed and BM was harvested from tibiae, femurs, humeri and pelvis. BM cells were cultured and transduced with VSV-Phl p 5 or mock transduced as described by Bagley et al 27 with a multiplicity of infection (MOI) of 3-5.

Bone marrow transplantation

One day before BMT, recipients received 8 Gy total body irradiation (TBI) and a depleting dose of anti-CD8 (2.43; 0.5mg/mouse) and anti-CD4 (GK1.5; 0.5mg/mouse) monoclonal antibodies (mAb). On the day of reconstitution mice were transplanted with 2-4×106 transduced BM cells intravenously. After BMT mice received anti-CD40L mAb (MR1; 0.5mg/mouse). Anti-CD4, anti-CD8 and anti-CD40L were used as they were shown to enhance engraftment of transduced BM. 28 All mAb used in vivo were purchased from Bioexpress (New Lebanon, NH).

Recombinant allergens and immunization of mice

Purified recombinant (r) timothy grass pollen and birch pollen allergens (rPhl p 5, rBet v 1) were obtained from Biomay (Vienna, Austria). All groups of mice were immunized subcutaneously with 5 μg rPhl p 5 and 5μg rBet v 1 adsorbed to aluminumhydroxid (Alu-Gel-S, Serva, Ingelheim, Germany) as described previously. 29

Secondary BMT

Forty weeks after BMT, BM cells were harvested from primary recipients and transplanted into secondary BALB/c mice preconditioned like primary recipients (described above). Each secondary recipient received 3×107 BM cells harvested from one chimera.

Flowcytometric analysis

Non-specific Fcγ receptor binding was blocked with mAb against mouse FcγII/III receptor (CD16/CD32). Phl p 5 polyclonal antiserum against full length rPhl p 5 was purified from rabbit serum (Charles River) by a protein G column (Pierce, Rockford, USA) according to the manufacturer's instructions. Polyclonal anti-Phl p 5 IgG was biotinylated and developed with phycoerythrin streptavidin. To detect Phl p 5+ expressing cells among various leukocyte lineages white blood cells were stained with FITC-conjugated antibodies against CD4, CD8, B220, Mac-1 and isotype controls (all antibodies from Pharmingen, San Diego, CA) and analyzed by flow cytometry. Propidium iodide staining was used to exclude dead cells. Two-color flow cytometric analysis was used to determine the percentage of Phl p 5-expressing cells of particular lineages. The percentage of Phl p 5+ cells (i.e. molecular chimerism) was calculated by subtracting control staining from quadrants containing Phl p 5+ and Phl p 5 negative cells expressing a particular lineage marker, and by dividing the net percentage of Phl p 5+ cells by the total net percentage of Phl p 5+ plus Phl p 5 negative cells of that lineage as described. 30 Mice were considered chimeric if they showed at least 1% Phl p 5 + cells within the myeloid lineage and at least one lymphoid lineage. An Epics XL-MCL flow cytometer (Beckman Coulter, IL Alliance, Vienna, Austria) was used for acquisition and EXPO32 ADC Software, Applied Cytometry Systems (West Sheffield, UK), was used for analysis of flow cytometric data.

ELISA

To measure antigen-specific antibodies in the sera of immunized mice ELISAs were performed as described previously. 31 Plates were coated with rPhl p 5 (5μg/ml), sera were diluted 1:20 for IgE, 1:100 for IgM, IgA, IgG2a and IgG3 respectively and 1:500 for IgG1 and bound antibodies were detected with monoclonal rat anti-mouse IgM, IgG1, IgE, IgA, IgG2a and IgG3 antibodies (Pharmingen, San Diego, CA) diluted 1:1000 and a HRP-coupled goat anti-rat antiserum (Amersham, Biosciences, UK) diluted 1:2000. The substrate for HRP was ABTS (60mM/l citric acid, 77mM/l Na2HPO4 × 2H2O, 1.7mM/l ABTS [Sigma, St. Lois, MO.], 3mM/l H2O2).

Lymphocyte proliferation assay

Spleens were removed under aseptic conditions (week 29/40) and homogenized. Suspended splenocytes were plated into 96-well round-bottom plates at a concentration of 2×105 cells / well in triplicates and stimulated with concanavalin A (Con A; 0.5μg/well, Sigma), rPhl p 5 (2μg/well) and rBet v 1 (2μg/well). On day 5 cultures were pulsed with 0.5μCi/well [3H]thymidine (Amersham, Biosciences, UK) and harvested approximately 16 hours thereafter. The proliferative response was measured by scintillation counting. The stimulation index (SI) was calculated as the ratio of the mean proliferation after allergen stimulation and medium control values. 32

Rat basophil leukaemia (RBL) cell degranulation assay

RBL-2H3 cell subline 33 was cultured as described previously 34, in RPMI 1640 medium (Biochrome AG, Berlin, Germany) containing 10 % fetal calf serum. 4×104 cells were plated in 96 well tissue culture plates (Greiner, Bio-One, Stuttgart, Germany), loaded with 1:50 diluted mouse sera and incubated for 2 hours at 37°C and 5 % CO2. Supernatants were removed and the cell layer was washed with 2x Tyrode's buffer (137 mM NaCl, 2.7 mM KCL, 0.5mM MgCl2, 1.8mM CaCl2, 0.4mM NaH2PO4, 5.6mM D-glucose, 12mM NaHCO3, 10mM HEPES and 0.1 % w/v BSA, pH 7.2). Preloaded cells were stimulated with rPhl p 5 or rBet v 1 (0.03μg per well) for 30 min. at 37°C. The supernatants were analyzed for ß-hexosaminidase activity by incubation with the substrate 80μM 4-methylumbelliferyl-N-acetyl-ß-D-glucosamide (Sigma-Aldrich, Vienna, Austria) in citrate buffer (0.1M, pH4.5) for 1 hour at 37°C. The reaction was stopped by addition of 100μl glycine buffer (0.2M glycine, 0.2M NaCl, pH 10.7) and the fluorescence was measured at λex: 360/λem: 465nm using a fluorescence microplate reader (Wallac, Perkin Elmer, Vienna, Austria). Results are reported as percentage of total ß-hexosaminidase released after addition of 1 % Triton X-100. Determinations were done in triplicates and are displayed as mean value + SD.

Cutaneous type I hypersensitivity reaction

Thirty weeks after BMT mice were injected intravenously with 100μl of 0.5 % Evans blue (Sigma, St. Louis, MO). Subsequently, 30μl of rPhl p 5 and rBet v 1 (0.5μg/ml each, diluted in PBS) were injected intradermally into the shaved abdominal skin as described previously. 35 As positive control, the mast cell-degranulating compound 48/80 (20μg/ml, Sigma) was injected intradermally whereas PBS was injected as a negative control. Twenty minutes after injection, mice were sacrificed and the blue colour intensity of a positive skin reaction due to vascular permeability was compared with the individual positive and negative control on the inverted skin.

Statistical analysis

The reported p-values are results of Wilcoxon-Mann-Whitney U test and exact significances. SPSS statistical software system 14.0 was used for calculations. P-values ≤ 0.05 were considered statistically significant. Error bars indicate standard deviations (SD).

RESULTS

Membrane-anchored expression of an allergen on murine BM after retroviral transduction

We generated a membrane-anchored fusion protein of full-length Phl p 5 (phleum pratense 5, timothy grass), 36 one of the most relevant respiratory allergens. The fusion gene was cloned into retroviral backbone pMMP 37 (Fig. 1A). Transient co-transfection of plasmids carrying viral structural proteins and Vesicular Stomatitis Virus G protein (VSV-G) envelope and pMMP-Phl p 5-TM into 293T cells resulted in VSV-Phl p 5-TM pseudotyped recombinant retroviruses. 27 BALB/c donors were treated with 5-fluorouracil, BM was isolated seven days later, cultured ex vivo and transduced with VSV-Phl p 5-TM retrovirus. Following transduction 35% and 55% of BM cells, respectively (in two independent experiments), expressed Phl p 5 on their membrane (Fig. 1B).

Figure 1
Efficient retroviral transduction of BM with membrane-bound allergen

Long-term molecular chimerism after transplantation of allergen-transduced HSC

Transduced BM cells were transplanted into pre-conditioned BALB/c recipients (Fig. 2A). The percentage of cells expressing Phl p 5 among various leukocyte lineages (i.e. molecular chimerism) was determined in blood by flow cytometry at multiple time points post-BM transplantation (BMT). All mice transplanted with Phl p 5-transduced BM (n= 10) developed high levels of chimerism in all tested lineages (e.g. 11% Phl p 5+ B cells and 22% Phl p 5+ T cells, 25 weeks post-BMT). Multi-lineage chimerism persisted throughout follow-up (> 39 weeks) (Fig. 2B). Comparable levels of chimerism in recipients of Phl p 5-transduced BM were also found in spleen and BM at the time of sacrifice (data not shown). Recipients of mock-transduced BM did not show any detectable Phl p 5-expression on leukocytes (data not shown). Persistent multi-lineage chimerism beyond 39 weeks in recipients of Phl p 5-transduced BM is indicative of successful transduction and engraftment of HSC. 38 To directly test whether HSC had been successfully transduced with Phl p 5-integrating recombinant retroviruses we harvested BM cells from Phl p 5 chimeras 40 weeks post-BMT and transplanted them into myeloablatively irradiated secondary BALB/c recipients (n= 3). Multi-lineage chimerism was again detectable and persisted for the length of follow up (15 weeks after secondary BMT, Fig. 2C), demonstrating that HSC had indeed been transduced to express Phl p 5 and had successfully engrafted and survived in the primary recipients.

Figure 2
Transplantation of syngeneic HSC retrovirally transduced to express Phl p 5 leads to high levels of permanent multi-lineage molecular chimerism

Specific absence of Phl p 5-specific humoral responses in recipients of Phl p 5-transduced BM

To assess whether tolerance was induced, we employed an established model in which Phl p 5-immunized BALB/c mice develop characteristics of clinical type I allergy such as production of allergen-specific IgE, other allergen-specific isotypes and IgE-mediated effector cell degranulation. 29;39 Following this protocol we sensitized BMT recipients through repeated immunization with the recombinant allergens Phl p 5 and an unrelated control allergen, the major birch pollen allergen Bet v 1 (Fig. 2A). No Phl p 5-specific IgE was detectable in sera of any of the Phl p 5 chimeric mice throughout follow-up as determined by ELISA (Fig. 3A). In contrast, Phl p 5 chimeric mice developed high levels of Bet v 1-specific IgE post-immunization (Fig. 3A). Recipients of mock-transduced BM (n= 3) and non-BMT immunized mice (i.e. naïve mice treated with the same immunization regimen but not receiving BMT, n= 10) developed high levels of IgE in response to both allergens. Likewise, Phl p 5-chimeras developed no Phl p 5-specific IgG1 whereas recipients of mock-transduced BM and non-BMT immunized mice showed high levels of Phl p 5-specific IgG1 upon repeated immunizations (Fig. 3B). Bet v 1-specific IgG1 levels were comparably high in all groups of mice. Similar results were obtained for allergen-specific IgA, IgG2a and IgG3 (Fig. 3C-E). Phl p 5-specific low affinity IgM could be detected in sera of Phl p 5 chimeras (Fig. 3F) reminiscent of natural autoantibodies directed against self-antigen. 40 Thus transplantation of Phl p 5-transduced BM led to specific tolerance towards the allergen at the B cell level, preventing the production of allergen-specific IgE and other high affinity isotypes.

Figure 3
Recipients of Phl p 5-transduced BM are specifically tolerant towards Phl p 5 at the B cell level

Specific T cell unresponsiveness in recipients of Phl p 5-transduced BM

In the course of an IgE-mediated allergic immune reaction, antigen-presenting cells induce activation and proliferation of allergen-specific T cells. 1;2 We therefore determined T cell responsiveness in in vitro proliferation assays by stimulating splenocytes isolated from recipients of Phl p 5-transduced BM with Phl p 5 and Bet v 1. The lymphocytes were isolated at the end of follow up from chimeric mice of two independent experiments 40 weeks and 29 weeks after BMT, respectively (Fig. 4A and B). Proliferation in response to Phl p 5 was reduced by 90% in recipients of Phl p 5-transduced BM cells compared to proliferation of splenocytes from non-BMT immunized mice (stimulation indices of 21 vs. 219, P= 0.006) (Fig. 4A). In contrast, the proliferation response to Bet v 1 was high both in Phl p 5 chimeras and non-BMT immunized controls (Fig. 4B). Thus recipients of Phl p 5-transduced BM showed allergen-specific T cell tolerance.

Figure 4
Recipients of Phl p 5-transduced BM are specifically tolerant towards Phl p 5 at the T cell level

IgE-mediated degranulation of basophils and mast cells is specifically abolished in recipients of Phl p 5-transduced BM

Cross-linking of IgE on tissue mast cells and basophils by allergens results in local release of inflammatory mediators (including histamine) which cause many symptoms of the acute phase of an allergic reaction. 41 We therefore analyzed effector cell function in vitro and in vivo. In a rat basophil leukemia (RBL) degranulation assay sera from Phl p 5 chimeras and control groups were loaded onto RBL-cells, and mediator release (ß-hexosaminidase as surrogate marker for histamine 33 was measured after challenge with allergen. In recipients of Phl p 5-transduced BM no mediator release was detectable in response to Phl p 5 while release occurred upon challenge with Bet v 1 (Fig. 5A and B). Non-BMT immunized mice and recipients of mock-transduced BM cells showed mediator release in response to both Phl p 5 and Bet v 1. To investigate anaphylactic activity of skin mast cells in vivo we measured allergen-specific immediate-type hypersensitivity responses by intradermal allergen challenge and Evans blue staining. No positive skin reaction was detectable after intradermal challenge with Phl p 5 in 6 of 7 tested Phl p 5 chimeric mice, while a positive reaction was visible in all mice upon Bet v 1 challenge (Fig. 6B). Non-BMT immunized mice showed positive skin reactions to both allergens (Fig. 6A). In contrast naïve BALB/c mice did not show any mast cell skin reaction upon allergen challenge (Fig. 6C). The results from these in vitro and in vivo assays reveal that recipients of Phl p 5-transduced BM developed allergen-specific tolerance at the effector cell level.

Figure 5
Recipients of Phl p 5-transduced BM are specifically tolerant towards Phl p 5 at the effector cell level as determined in vitro
Figure 6
Recipients of Phl p 5-transduced BM are specifically tolerant towards Phl p 5 at the effector cell level as determined by type I allergen-specific skin responses in vivo

DISCUSSION

The data presented herein provide proof of concept that tolerance towards an allergen can be induced through transplantation of genetically modified BM. This novel approach for tolerizing a type I allergic immune response has two unique characteristics: permanence and robustness. Tolerance persisted for the length of follow up (40 weeks). As our data point to the successful engraftment of HSC transduced with the allergen, it appears safe to assume that molecular chimerism would persist for the physiological lifespan of the recipient and would continue to maintain tolerance. With this approach all relevant levels of a type I allergic immune response, namely T cells, B cells and effector cells, were rendered specifically tolerant towards the immunogenic grass pollen allergen used in these experiments for BM transduction. Notably, allergen-specific IgE, IgG subtypes and IgA remained undetectable throughout follow-up. Besides, T cell responses and effector cell responses towards the allergen could not be detected. A comparably complete degree of tolerance has to the best of our knowledge not been reported with other experimental or clinical approaches that have been employed for allergy treatment or prevention.

Allergen-specific immunotherapy, the only causative treatment of allergy currently available in the clinical setting, was suggested to lead to immunomodulation of T cell responses in large part through the induction of a Th1 shift and the generation of regulatory T cells. Additionally, the humoral response is affected by the induction of high levels of allergen-specific IgG (and other isotypes) which is then competing with allergen-specific IgE. 4 At the experimental level, dominant T cell epitope-containing polypeptides of three different allergens were administered intranasally in a murine mucosal tolerance approach. After subsequent sensitization with allergens, allergen-specific humoral and effector cell responses were merely reduced but not completely prevented. 10 Another recently published approach relied on the blockade of the ICOS-ICOS-ligand pathway which induced regulatory T cells and inhibited OVA-induced airway hyperreactivity, but OVA-specific IgE was still detectable. 9 A fusion protein consisting of an allergen and a truncated Fcγ1 portion which was designed for the purpose of immunomodulation was shown to inhibit allergen-induced basophil and mast cell degranulation by co-crosslinking of FcεRI and Fcγ receptors (follow-up ~6 weeks), but did not prevent antibody production. 11 Overall, the causative approaches described in the literature so far, as exemplified above, led to immunomodulation and reduction of an allergic reaction, but not to the complete, permanent absence of all relevant levels of an allergen-specific immune response. Molecular chimerism, in contrast, establishes such a state of complete tolerance towards an allergen. While detailed mechanistic studies are beyond the scope of this manuscript, we consider it likely that central tolerance plays a critical role in our model, as it does in all chimerism-based protocols 16. However, non-deletional mechanisms, in particular T regulatory cells, might also be of importance, as we have recently shown in an allogeneic mixed chimerism model 42;43.

Previously it had been shown that molecular chimerism can be used to tolerize allogeneic and xenogeneic immune responses, not only in rodents, but also in large animals. 20;27;44 This concept failed, however, in a specific autoimmune model for unclear reasons. 23 Thus, while molecular chimerism overall is a highly attractive tolerance approach, its effectiveness needs to be individually assessed for each particular immune response and regimens potentially need to be adapted accordingly. To the best of our knowledge, none of the reported molecular chimerism studies have investigated IgE responses and none have employed allergens.

Transplantation of retrovirally transduced BM has been able to correct life-threatening lymphoid and myeloid immunodeficiencies in the clinical setting 45;46, but was associated with serious side effects. 47 However, substantial advances in vector design are continuously being achieved so that safe vectors may some day become available. 47;48 Molecular chimerism relies on the transplantation of autologous BM modified to differ in a single antigen (or at most a small, limited number of antigens) thereby avoiding GVHD, one of the gravest risks associated with allogeneic BMT and cellular chimerism. Minimally toxic regimens for recipient conditioning have recently been developed for the experimental transplantation of allogeneic BM which could eventually also be employed for the molecular chimerism approach. 15,30,49,50 Besides, autologous and allogeneic BMT have become a therapeutic option in selected clinical cases of autoimmune disease and the range of indications for which BMT is a valid treatment is expected to increase substantially over the coming years. 51,52

According to advances made in the field of molecular allergen characterization a limited number (approx. 30) of major and clinically relevant allergens can be defined which cover the most relevant allergen sources 6. Using the recently described hybrid technology it should be possible to engineer a few hybrid molecules (5-6) which may be sufficient to tolerize populations against the most common allergen sources in certain areas 53.

The concept presented here provides a novel cell-based approach for tolerizing a type I allergic immune response through transplantation of genetically modified hematopoietic cells. As most relevant allergens have been cloned this approach may theoretically be used for the prevention of many common forms of allergy.

ACKNOWLEDGEMENTS

We thank Christian Lupinek for helpful assistance with statistical calculations.

Footnotes

1This work was supported by the Austrian Science Fund (FWF, F2310 to T.W. and FWF, F1815 to R.V.), and in part by the Christian Doppler Association and a research grant from Biomay.

REFERENCES

1. Coffman RL. Origins of the TH1-TH2 model: a personal perspective. Nat Immunol. 2006;7:539–541. [PubMed]
2. Romagnani S. Regulation of the development of type 2 T-helper cells in allergy. Curr Opin Immunol. 1994;6:838–846. [PubMed]
3. Moneret-Vautrin DA, Morisset M, Flabbee J, Beaudouin E, Kanny G. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy. 2005;60:443–451. [PubMed]
4. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6(10):761–71. [PubMed]
5. Valenta R. The future of antigen-specific immunotherapy of allergy. Nature Rev Immunol. 2002;2:446–453. [PubMed]
6. Linhart B, Valenta R. Molecular design of allergy vaccines. Curr Opin Immunol. 2005;17:646–655. [PubMed]
7. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nature Med. 2005;11:S69–S76. [PubMed]
8. Hessel EM, Chu M, Lizcano JO, Chang B, Herman N, Kell SA, Wills-Karp M, Coffman RL. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J. Exp. Med. 2005;202:1563–1573. [PMC free article] [PubMed]
9. Akbari O, Freeman GJ, Meyer EH, Greenfield EA, Chang TT, Sharpe AH, Berry G, DeKruyff RH, Umetsu DT. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nature Med. 2002;8:1024–1032. [PubMed]
10. Hufnagl K, Winkler B, Focke M, Valenta R, Scheiner O, Renz H, Wiedermann U. Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice. J. Allergy Clin. Immunol. 2005;116:370–376. [PubMed]
11. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nature Med. 2005;11:446–449. [PubMed]
12. von Boehmer H, Kisielow P. Negative selection of the T-cell repertoire: where and when does it occur? Immunol. Rev. 2006;209:284–289. [PubMed]
13. Brocker T, Riedinger M, Karjalainen K. Targeted expression of major histocompatibility complex (MHC) demonstrates that dendritic cells can induce negative but not positive selection in vivo. J.Exp.Med. 1997;185:541–550. [PMC free article] [PubMed]
14. Hartley SB, Crosbie J, Brink RA, Kantor AB, Basten A, Goodnow CC. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature. 1991;353:765–769. [PubMed]
15. Wekerle T, Kurtz J, Ito H, Ronquillo JV, Dong V, Zhao G, Shaffer J, Sayegh MH, Sykes M. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nature Med. 2000;6:464–469. [PubMed]
16. Wekerle T, Sykes M. Mixed chimerism and transplantation tolerance. Annu Rev Med. 2001;52:353–370. [PubMed]
17. Bagley J, Bracy J, Tian C, Kang E-S, Iacomini J. Establishing immunological tolerance through the induction of molecular chimerism. Frontiers in Bioscience. 2002;7:1333–1337. [PubMed]
18. Madsen JC, Superina RA, Wood KJ, Morris PJ. Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes. Nature. 1988;332:161–164. [PubMed]
19. Kang E-S, Iacomini J. Induction of central deletional T cell tolerance by gene therapy. J Immunol. 2002;169:1930–1935. [PubMed]
20. Bracy JL, Sachs DH, Iacomini J. Inhibition of xenoreactive natural antibody production by retroviral gene therapy. Science. 1998;281:1845–1847. [PubMed]
21. Alderuccio F, Murphy K, Toh B-H. Stem cells engineered to express self-antigen to treat autoimmunity. Trend Immunol. 2003;24:176–180. [PubMed]
22. Steptoe RJ, Ritchie JM, Harrison LC. Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes. J Clin Invest. 2003;111:1357–1363. [PMC free article] [PubMed]
23. Peters TR, Bodine DM, McDonagh KT, Lovett-Racke A, McFarland HF, McFarlin DE, Nienhuis AW, Racke MK. Retrovirus mediated gene transfer of the self antigen MBP into the bone marrow of mice alters resistance to experimental autoimmune encephalomyelitis. J Neuroimmunol. 2000;103:51–62. [PubMed]
24. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989;77:51–59. [PubMed]
25. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA. 1993;90:8392–8396. [PubMed]
26. Bodine DM, McDonagh KT, Seidel NE, Nienhuis AW. Survival and retrovirus infection of murine hematopoietic stem cells in vitro: effects of 5-FU and method of infection. Exp.Hematol. 1991;19:206–212. [PubMed]
27. Bagley J, Tian C, Sachs DH, Iacomini J. Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy. Blood. 2002;99:4394–4399. [PubMed]
28. Bagley J, Tian C, Sachs DH, Iacomini J. T cells mediate resistance to genetically modified bone marrow in lethally irradiated recipients. Transplantation. 2002;74:1454–1460. [PubMed]
29. Linhart B, Bigenzahn S, Hartl A, Lupinek C, Thalhamer J, Valenta R, Wekerle T. Costimulation Blockade Inhibits Allergic Sensitization but Does Not Affect Established Allergy in a Murine Model of Grass Pollen Allergy. J Immunol. 2007;178:3924–3931. [PMC free article] [PubMed]
30. Blaha P, Bigenzahn S, Koporc Z, Schmid M, Langer F, Selzer E, Bergmeister H, Wrba F, Kurtz J, Kiss C, Roth E, Muehlbacher F, Sykes M, Wekerle T. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood. 2003;101:2886–2893. [PubMed]
31. Vrtala S, Sperr W, Reimitzer I, van Ree R, Laffer S, Muller W, Valent P, Lechner K, Rumpold H, Kraft D. cDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen; characterization of the recombinant Phl pV allergen. J Immunol. 1993;151:4773–4781. [PubMed]
32. Valenta R, Ball T, Focke M, Linhart B, Mothes N, Niederberger V, Spitzauer S, Swoboda I, Vrtala S, Westritschnig K, Kraft D. Immunotherapy of Allergic Disease. Adv. Immunol. 2004;82:105–153. [PubMed]
33. Hoffmann A, Jamin A, Foetisch K, May S, Aulepp H, Haustein D, Vieths S. Determination of the allergenic activity of birch pollen and apple prick test solutions by measurement of beta-hexosaminidase release from RBL-2H3 cells. Comparison with classical methods in allergen standardization. Allergy. 1999;54(5):446–54. [PubMed]
34. Rauter I, Krauth M-T, Flicker S, Gieras A, Westrischnig K, Vrtala S, Balic N, Spitzauer S, Huss-Marp J, Brockow K, Darsov U, Ring J, Behrendt H, Semmper H, Valent P, Valenta R. Allergen cleavage by effector cell-derived proteases regulates allergic inflammation. FASEB J. 2006;20(7):967–9. [PubMed]
35. Wiedermann U, Jahn-Schmid B, Bohle B, Repa A, Renz H, Kraft D, Ebner C. Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant Bet v 1,the major birch pollen allergen, in a murine model of type I allergy. J. Allergy Clin. Immunol. 1999;103(6):1202–10. [PubMed]
36. Vrtala S, Ball T, Spitzauer S, Pandjaitan B, Suphioglu C, Knox B, Sperr WR, Valent P, Kraft D, Valenta R. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. J Immunol. 1998;160:6137–6144. [PubMed]
37. Riviere I, Brose K, Mulligan R. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA. 1995;92:6733–6737. [PubMed]
38. Down JD, Ploemacher RE. Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs. Exp.Hematol. 1993;21:913–921. [PubMed]
39. Herz U, Renz H, Wiedermann U. Animal models of type I allergy using recombinant allergens: Recombinant allergens. Methods. 2004;32:271–280. [PubMed]
40. Hardy RR. B-1 B cells: development, selection, natural autoantibody and leukemia: Innate lymphocytes/Transplantation/Immunogenetics. Curr Opin Immunol. 2006;18:547–555. [PubMed]
41. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nature Rev. Immunol. 2007;7:93–104. [PubMed]
42. Kurtz J, Wekerle T, Sykes M. Tolerance in mixed chimerism - a role for regulatory cells? Trends Immunol. 2004;25:518–523. [PubMed]
43. Bigenzahn S, Blaha P, Koporc Z, Pree I, Selzer E, Bergmeister H, Wrba F, Heusser C, Wagner K, Muehlbacher F, Wekerle T. The role of non-deletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade. Am J Transplant. 2005;5:1237–1247. [PubMed]
44. Sonntag KC, Emery DW, Yasumoto A, Haller G, Germana S, Sablinski T, Shimizu A, Yamada K, Shimada H, Arn S, Sachs DH, LeGuern C. Tolerance to solid organ transplants through transfer of MHC class II genes. J Clin Invest. 2001;107:65–71. [PMC free article] [PubMed]
45. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay J-P, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo M. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185–1193. [PubMed]
46. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kuhlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Luthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 2006;12:401–409. [PubMed]
47. Baum C, Dullmann J, Li Z, Fehse B, Meyer J, Williams DA, von Kalle C. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 2003;101:2099–2113. [PubMed]
48. Ferguson C, Larochelle A, Dunbar CE. Hematopoietic stem cell gene therapy: dead or alive? Trends in Biotechnology. 2005;23:589–597. [PubMed]
49. Pree I, Pilat N, Wekerle T. Recent progress in tolerance induction through mixed chimerism. Int Arch Allergy Immunol. 2007;144:254–66. [PubMed]
50. Wekerle T, Nikolic B, Pearson DA, Swenson KG, Sykes M. Minimal conditioning required in a murine model of T cell depletion, thymic irradiation and high-dose bone marrow transplantation for the induction of mixed chimerism and tolerance. Transpl Int. 2002;15:248–253. [PubMed]
51. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;345:1813–1826. [PubMed]
52. Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature. 2005;435:620–627. [PubMed]
53. Linhart B, Valenta R. Vaccine engineering improved by hybrid technology. Int Arch Allergy Immunol. 2004;134:324–31. [PubMed]